<--- Back to Details
First PageDocument Content
Intensive care medicine / Muscular dystrophy / Motor neurone disease / Mechanical ventilation / Muscular Dystrophy Association / Duchenne muscular dystrophy / Pulmonary function testing / Respiratory failure / Amyotrophic lateral sclerosis / Medicine / Health / Respiratory therapy
Date: 2012-01-05 13:46:00
Intensive care medicine
Muscular dystrophy
Motor neurone disease
Mechanical ventilation
Muscular Dystrophy Association
Duchenne muscular dystrophy
Pulmonary function testing
Respiratory failure
Amyotrophic lateral sclerosis
Medicine
Health
Respiratory therapy

Breathe Easy Respiratory Care in Neuromuscular Disorders The Muscular Dystrophy Association is a voluntary health agency aimed at conquering more than 40

Add to Reading List

Source URL: static.mda.org

Download Document from Source Website

File Size: 814,36 KB

Share Document on Facebook

Similar Documents

Microsoft Word - ASX 17_ 2 October_ ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update summary_Final

Microsoft Word - ASX 17_ 2 October_ ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update summary_Final

DocID: 1ulfx - View Document

19 DecemberATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update Antisense Therapeutics Limited (“ANP” or “the Company”) provides the following update on the progress of its Multiple Sclero

19 DecemberATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update Antisense Therapeutics Limited (“ANP” or “the Company”) provides the following update on the progress of its Multiple Sclero

DocID: 1tPwS - View Document

FINAL  Catabasis Pharmaceuticals Announces the Initiation of an Open-Label Extension for the MoveDMD® Trial Studying Edasalonexent (CATin Duchenne Muscular Dystrophy CAMBRIDGE, MA, July 7, 2016 – Catabasis Phar

FINAL Catabasis Pharmaceuticals Announces the Initiation of an Open-Label Extension for the MoveDMD® Trial Studying Edasalonexent (CATin Duchenne Muscular Dystrophy CAMBRIDGE, MA, July 7, 2016 – Catabasis Phar

DocID: 1t5Sx - View Document

Screening S. aureus CRISPR-Cas9 Paired Guide RNAs for Efficient Targeted Deletion in Duchenne Muscular Dystrophy Josh Tycko1, Nick Huston1, Jacqueline Robinson-Hamm2, Chris Wilson1, Charles A. Gersbach2, Patrick D. Hsu1,

Screening S. aureus CRISPR-Cas9 Paired Guide RNAs for Efficient Targeted Deletion in Duchenne Muscular Dystrophy Josh Tycko1, Nick Huston1, Jacqueline Robinson-Hamm2, Chris Wilson1, Charles A. Gersbach2, Patrick D. Hsu1,

DocID: 1sCDI - View Document

Research Review No. 96. Therapeutic effect of simvastatin to Duchenne Muscular Dystrophy. The Studies: The authors of this study (1) from U.S.A. note in their introduction that Duchenne muscular dystrophy (DMD) is a le

DocID: 1rWwv - View Document